Drug Information

Drug General Information
Drug ID
D06KKN
Former ID
DIB020267
Drug Name
LY2109761
Synonyms
LY-2109761; LY 2109761
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529427]
Structure
Download
2D MOL
Formula
C26H27N5O2
InChI
InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2
InChIKey
IHLVSLOZUHKNMQ-UHFFFAOYSA-N
PubChem Compound ID
11655119
PubChem Substance ID
16758637, 23756605, 49700621, 79852234, 103566348, 135723828, 136349564, 136367695, 137275861, 139858820, 144116157, 152159574, 152255061, 152258391, 152344392, 160647228, 162011469, 165246685, 172914060, 174006493, 174530316, 176237647, 180399204, 184816025, 208265510, 215783135, 223387286, 223438197, 223574706, 223705045, 225130378, 229727789, 242060149, 243147086, 245563668, 249565755, 249862162, 250207140, 252077501, 252215727, 252438714, 252553671
Target and Pathway
Target(s) TGF-beta receptor type I Target Info Inhibitor [529427]
TGF-beta type II receptor Target Info Inhibitor [529427]
KEGG Pathway MAPK signaling pathway
Cytokine-cytokine receptor interaction
FoxO signaling pathway
Endocytosis
TGF-beta signaling pathway
Osteoclast differentiation
Hippo signaling pathway
Adherens junction
Chagas disease (American trypanosomiasis)
Hepatitis B
HTLV-I infection
Pathways in cancer
Colorectal cancer
Pancreatic cancer
Chronic myeloid leukemiahsa04010:MAPK signaling pathway
Transcriptional misregulation in cancer
Chronic myeloid leukemia
NetPath Pathway FSH Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
Pathway Interaction Database Glypican 1 network
ALK1 signaling events
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
TGF-beta receptor signalingglypican_1pathway:Glypican 1 network
Beta3 integrin cell surface interactions
Integrins in angiogenesis
TGF-beta receptor signaling
Reactome TGF-beta receptor signaling activates SMADs
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
SMAD2/3 Phosphorylation Motif Mutants in Cancer
SMAD2/3 MH2 Domain Mutants in Cancer
TGFBR2 Kinase Domain Mutants in Cancer
TGFBR1 KD Mutants in Cancer
TGFBR1 LBD Mutants in CancerR-HSA-2173789:TGF-beta receptor signaling activates SMADs
TGFBR1 LBD Mutants in Cancer
WikiPathways TGF Beta Signaling Pathway
p38 MAPK Signaling Pathway
MAPK Signaling Pathway
TGF beta Signaling Pathway
Extracellular vesicle-mediated signaling in recipient cells
Cardiac Hypertrophic Response
Signaling by TGF-beta Receptor Complex
Integrated Pancreatic Cancer Pathway
Integrated Breast Cancer PathwayWP560:TGF Beta Signaling Pathway
NRF2 pathway
Nuclear Receptors Meta-Pathway
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
miR-targeted genes in adipocytes - TarBase
Integrated Breast Cancer Pathway
References
Ref 529427LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40.
Ref 529427LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.